News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

CEL-SCI (CVM) Hires Two CROs; Multikine Phase III Trial Being Expanded

4/24/2013 9:35:58 AM

On April 23, 2013, CEL-SCI Corporation announced that the company hired two clinical research organizations, Aptiv Solutions and Ergomed, to manage the Multikine phase III study. Both CROs will help CEL-SCI expand the trial by 60 to 80 clinical sites globally. Aptiv Solutions and Ergomed have replaced the CRO currently managing the study.

Under a co-development agreement, Ergomed, which will be responsible for most of the new patient enrollment, will contribute up to $10 million towards the study. Ergomed will perform clinical services in exchange for milestone and royalty payments (single digit %) up to a specified maximum amount.

To date, the phase III trial has enrolled 117 patients at 39 centers in eight countries, including three centers in Israel, and nine centers in Taiwan.

It is never our intention to send unsolicited email. You are receiving this because you have consented to receive email correspondence on this subject matter. If you no longer want to receive emails from Taglich Brothers, Inc., please use the “unsubscribe” button at the bottom of this email or email us at with the subject “unsubscribe” and we will manually remove you promptly. Please include your full name so that we can locate your information quickly and efficiently.

Company Description:

CEL-SCI Corporation (NYSE: CVM), headquartered in Vienna, Virginia, is a development stage biopharmaceutical company focused on unique immunotherapies that address unmet needs in significant patient populations.

In recent years, the company’s R&D has centered on immunotherapy for head and neck cancer, which now absorbs practically all of its R&D spending. Product development includes work on LEAPS (Ligand Epitope Antigen Presentation System) technology treatments for a range of influenzas and a vaccine against rheumatoid arthritis.

The company’s lead drug candidate, Multikine®, is a synthesized combination, non-specific immunotherapy currently being evaluated in a phase III study as neoadjuvant therapy for advanced primary (untreated) head and neck cancer.

Multikine is under study in a 48-center, 800+ subject phase III clinical trial that aims to demonstrate that it can, in combination with follow-on surgery, radiation and chemotherapy, reduce mortality in advanced head and neck cancer cases by 10%. The therapy aims to reduce mortality by eradicating micro-metastases, microscopic tumors that survive the therapy, are difficult to detect, and are arguably the underlying cause of disease recurrence.

Multikine has orphan drug status in the US.

Taglich Brothers:

Taglich Brothers, Inc. is full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

The Taglich Brothers' Equity Research department is dedicated to providing research reports that are informative, insightful and illuminating. Reports are designed to distill volumes of investment information into a concise, straightforward format so that busy professional investors can make informed investment decisions.


The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. In January 2013 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of three more months for such services.


Richard Oh


Read at

comments powered by Disqus